Patents by Inventor Yesseinia Anglero-Rodriguez

Yesseinia Anglero-Rodriguez has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITIONS AND METHODS FOR EPIGENETIC REGULATION OF HBV GENE EXPRESSION
    Publication number: 20240132855
    Abstract: This invention relates to compositions, methods, strategies, and treatment modalities related to the epigenetic modification of hepatitis B virus (HBV) genes.
    Type: Application
    Filed: September 25, 2023
    Publication date: April 25, 2024
    Inventors: Aron Brandon Jaffe, Noorussahar Abubucker, Yesseinia Anglero-Rodriguez, Vic Myer, Angelo Leone Lombardo, Martino Alfredo Cappelluti
  • TRANSMEMBRANE SERINE PROTEASE 2 (TMPRSS2) IRNA COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20230193284
    Abstract: The present invention relates to RNAi agents, e.g., dsRNA agents, targeting the transmembrane serine protein 2 (TMPRSS2) gene. The invention also relates to methods of using such RNAi agents to inhibit expression of a TMPRSS2 gene and to methods of treating or preventing a TMPRSS2-associated disease, e.g., COVID-19, in a subject.
    Type: Application
    Filed: September 30, 2022
    Publication date: June 22, 2023
    Inventors: Akin Akinc, James D. McIninch, Yesseinia Anglero-Rodriguez, Mark K. Schlegel
  • ANGIOTENSIN-CONVERTING ENZYME 2 (ACE2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20230133147
    Abstract: The present invention relates to RNAi agents, e.g., dsRNA agents, targeting the angiotensin converting enzyme 2 (ACE2) gene. The invention also relates to methods of using such RNAi agents to inhibit expression of an ACE2 gene and to methods of treating or preventing an ACE2-associated disease, e.g., COVID-19, in a subject.
    Type: Application
    Filed: September 30, 2022
    Publication date: May 4, 2023
    Inventors: Akin Akinc, James D. McIninch, Yesseinia Anglero-Rodriguez, Mark K. Schlegel
  • CORONAVIRUS IRNA COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20220127615
    Abstract: The present invention relates to RNAi agents, e.g., dsRNA agents, targeting the coronavirus genome. The invention also relates to methods of using such RNAi agents to inhibit expression of a coronavirus genome and to methods of treating or preventing a coronavirus-associated disease in a subject.
    Type: Application
    Filed: November 10, 2021
    Publication date: April 28, 2022
    Inventors: Akin Akinc, James D. McIninch, Yesseinia Anglero-Rodriguez, Mark K. Schlegel, Christy M. Hebner, Florian A. Lempp
  • Coronavirus iRNA compositions and methods of use thereof
    Patent number: 11208660
    Abstract: The present invention relates to RNAi agents, e.g., dsRNA agents, targeting the coronavirus genome. The invention also relates to methods of using such RNAi agents to inhibit expression of a coronavirus genome and to methods of treating or preventing a coronavirus-associated disease in a subject.
    Type: Grant
    Filed: May 17, 2021
    Date of Patent: December 28, 2021
    Assignees: Alnylam Pharmaceuticals, Inc., Vir Biotechnology, Inc.
    Inventors: Akin Akinc, James D. McIninch, Yesseinia Anglero-Rodriguez, Mark K. Schlegel, Christy M. Hebner, Florian A. Lempp